Capsulution is Starting In-vivo Tests at Charité
Innovative Formulation of a Hormone Compound for Tumor Therapy
Dr. Volker Fehring, Project Director at Capsulution, comments, “The in-vivo studies allow the efficient investigation of these new kinds of depot formulations on the pharmacokinetic, pharmacodynamic and histological levels. In combination with appropriate bioequivalence tests, Capsulution will get a deeper insight into the complex release and effective mechanisms and thus make it possible to fine-tune these depot formulations in a targeted manner.”
Upon successful conclusion of the tests, Capsulution and its partner are planning to further develop the product as fast as possible. Few contingency risks are expected on the way to regulatory approval of the finished formulations on the market. In contrast to the development of new chemical entities (NCE), the development of these formulations are based on active and excipient agents that have already been approved.
Über die Capsulution Pharma AG
Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.